Clinical Trials

NCT Number: NCT02960022 Phase: PHASE2 Trial Summary: The purpose of this study is to collect long term safety data in subjects who are continuing to derive clinical benefit from treatment with Enzalutamide from the subjects participation in an enzalutamide clinical study sponsored by Astellas or Medivation (i.e., parent study) which has completed, at a minimum, […]

NCT Number: NCT03495427 Phase: Phase 2|Phase 3 Trial Summary: This study will enroll 60 patients previously enrolled to MCC#18523, “A Validation Study on the Impact of Decipher® Testing on Treatment Recommendations in African-American and Non – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Acronym:

NCT Number: NCT02935205 Phase: Phase 1|Phase 2 Trial Summary: This phase I/II trial studies the side effects of enzalutamide and indomethacin and to see how well they work in treating patients with prostate cancer that does not respond to tre – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Acronym:

NCT Number: NCT02949284 Phase: Phase 2 Trial Summary: This randomized phase II trial studies how well androgen receptor antagonist ARN-509 works with or without abiraterone acetate, gonadotropin-releasing hormone agonist, and predniso – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Acronym:

NCT Number: NCT06101290 Phase: NA Trial Summary: This is a phase 2 pragmatic study that evaluates the clinical benefit of continuing systemic therapy with the addition of locally ablative therapies for oligo-progressive solid tumors as the primary o- clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Acronym: LAYOVER

NCT Number: NCT06105918 Phase: PHASE1 Trial Summary: This phase I trial tests the safety, side effects and best dose of radioligand therapy (lutetium Lu 177 PSMA-10.1 [177Lu-rhPSMA-10.1]) after prostate specific membrane antigen (PSMA) positron emissi- clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Acronym:

NCT Number: NCT02064673 Phase: Phase 3 Trial Summary: This is a prospective study to determine if the adjuvant use of Curcumin improves recurrence-free su – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Acronym:

NCT Number: NCT04019964 Phase: Phase 2 Trial Summary: MMR-deficient cancers of any histologic type appear to be very sensitive to PD-1 blockade with pembrolizumab, and similar data are also beginning to emerge for nivolumab and other – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Acronym:

NCT Number: NCT04175431 Phase: Phase 2 Trial Summary: This phase II trial studies how well fluciclovine positron emission tomography (PET)/computed tomography (CT) site-directed therapy works for treating patients with prostate cancer – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Acronym:

NCT Number: NCT06095089 Phase: PHASE1 Trial Summary: The purpose of the study is to determine the recommended regimen for Phase 2 (RP2Rs) of combination of JNJ-87189401 with JNJ-78278343 (Part 1: dose escalation) and further evaluate the safety at RP2Rs- clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Acronym: